BOSTON, MA--(Marketwired - October 20, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today presentations at two upcoming R&D conferences focused on immuno-oncology.
The details for each presentation are as follows:
American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston Marriott Copley Plaza, Boston, MA, October 20 - 23, 2016
Presentation Time: Friday, October 21, 2016, 5:15 pm‐7:45 pm, Back Bay room | |
Presentation: A poster presentation entitled, "Costimulatory T‐cell engagement by PRS‐343, a CD137 (4‐1BB)/HER2 bispecific, leads to tumor growth inhibition and CD8(+) T cell expansion in a humanized mouse model." |
Society of Immunotherapy of Cancer (SITC), Gaylord National Hotel & Convention Center, National Harbor, Maryland, November 9 - 13, 2016
Oral Presentation: An oral presentation entitled "PRS-343, a CD137 (4-1BB)/HER2 Bispecific" will be given on Wednesday, November 9, 2016, 11:50 am | |
Poster Presentation: New Cancer Immunotherapy -- A poster presentation will be presented on Saturday, November 12, 2016, 11:45 am - 1:00 pm and 6:45 pm - 8:00 pm |
About Pieris
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information visit www.pieris.com.
Company Contact:
Pieris Pharmaceuticals, Inc.
Darlene Deptula-Hicks
SVP & Chief Financial Officer
1-603-553-5803
[email protected]
Investor Relations Contact:
The Trout Group
Thomas Hoffmann
1-646-378-2931
[email protected]
Media Inquiries:
Gretchen Schweitzer
+49 172 861 8540
[email protected]
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member